{"task_id": "925fcfabf061c6bd", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 190/464)", "text": "ciprocal depression), urinary\n178\nMultiple Myeloma\n\n--- Page 200 ---\nINVESTIGATIONS (CONT\u2019D)\nprotein electrophoresis, 24 h urinary collection\nfor Bence Jones protein\n\u0002\nIMAGING\nskeletal survey\n\u0002\nBONE MARROW BIOPSY\n\u0002\nNOTE: light chain myeloma (20%) may have nor\nmal serum protein electrophoresis. Urinary\nBence Jones protein (urine protein electrophor\nesis) is required to detect paraproteinemia; non\nsecretatory myeloma (3%) requires bone mar\nrow biopsy for diagnosis\nRelated Topics\nAmyloidosis (p. 420)\nRenal Failure (p. 68)\nDIAGNOSTIC AND PROGNOSTIC ISSUES\nINTERNATIONAL MYELOMA WORKING GROUP\nCRITERIA\n\u0002\nMULTIPLE MYELOMA\n\u0002\nBONE MARROW PLASMA CELLS/PLASMACYTOMA\nno percent specified, but usually >10%\n\u0002 M-PROTEIN\nin serum and/or urine, no concen\ntration specified, but >30 g/L [>3 g/dL] in\nserum if overt myeloma\n\u0002\nTISSUE IMPAIRMENT\nwCRABw increased calcium\n(>2.75 mmol/L [>11 mg/dL]), renal insufficiency\n(Cr\n>173\nmmol/L\n[>1.9\nmg/dL]),\nanemia\n(Hb<100 g/L [<10 g/dL] or drop by 20 g/L\n[2 g/dL]), bone lesions (lytic lesions, fractures).\nOther features include hyperviscosity, amyloidosis,\nor recurrent infections (>2 episodes in 12 months)\n\u0002\nSMOLDERING MULTIPLE MYELOMA (SMM)\n\u0002\nBONE MARROW PLASMA CELLS\n>10%\n\u0002 M-PROTEIN\n>30 g/L [>3 g/dL] (but not neces\nsary if bone marrow plasma cells>10%)\n\u0002\nTISSUE IMPAIRMENT\nno symptoms\n\u0002\nMONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIF-\nICANCE (MGUS)\n\u0002\nBONE\nMARROW\nPLASMA\nCELLS\n<10% (bone\nmarrow biopsy is not required for suspected\nMGUS if M protein \b15 g/L [\b1.5 g/dL], IgG\nsubtype, and patient asymptomatic)\n\u0002 M-PROTEIN\n< 30 g/L[ <3g/dL]\n\u0002\nTISSUE IMPAIRMENT\nno symptoms\n\u0002\nCOURSE\noccurs in 2% of population over age 50\nand 3% over age 70. Rate of transformation to\nmalignant plasma cell disorder (multiple mye\nloma, Waldenstrom\u2019s macroglobulinemia, pri\nmary amyloidosis, B cell lymphoma, or chronic\nlymphocytic leukemia) is about 1% per year\nNEJM 2006 355:26\nDIAGNOSTIC CLUES\n\u0002\nSYMPTOMS\nthe presence of tissue impairment\nsuggests either multiple myeloma (usually high\nM protein) or amyloidosis (usually low M protein).\nAL amyloidosis is characterized by insoluble, toxic\namyloid precursor (light chains) aggregates that\ndeposit in tissues in antiparallel b pleated sheet\nconfiguration. The absence of symptoms suggests\nMGUS or SMM\n\u0002\nQUANTITATIVE\nIG\ntypically\ndecreased\nserum\nlevels of normal polyclonal immunoglobulins in\nmultiple myeloma. However, this may also occur\nin MGUS\n\u0002 BENCE\nJONES\nPROTEINURIA\nthe\npresence\nof\nmonoclonal light chains (especially >1 g/day) in\nthe urine suggests multiple myeloma. However,\nsmall amounts ( <50 mg/day) may also occur in\nMGUS\n\u0002\nSERUM M PROTEIN LEVEL\nthe higher the level,\nthe higher the likelihood of multiple myeloma.\nSome define 35 g/L [3.5 g/dL] for IgG and\n20 g/L [2 g/dL] for IgA as cutoff, others define\n30 g/L [3 g/dL] regardless of Ig subtype as\ncutoff\nDURIE SALMON STAGING FOR MULTIPLE MYELOMA\n\u0002\nSTAGE I (low tumor burden, <0.6\u00031012/m2)\nall\nof Hb >100 g/L [>10 g/dL], Ca2+\b2.6 mmol/L\n[\b10.4 mg/dL], bones normal or solitary bone\nplasmacytoma only, IgG <50 g/L [ <5 g/dL], IgA\n<30 g/L [ <3 g/dL], and urinary l or k chains\n<4 g/day. Median survival \u000560 months\n\u0002\nSTAGE II (intermediate burden, 0.6 1.2\u00031012/\nm2)\nbetween stages I and III. Median survival\n\u000530 months\n\u0002\nSTAGE III (high tumor burden, >1.2\u00031012/m2)\nany of\nHb <85 g/L [< 8.5 g/dL], Ca2+ >2.6 mmol/L\n[>10.4 mg/dL], >3 lytic lesions, plus one of IgG\n>70 g/L [>7 g/dL], IgA >50 g/L [>5 g/dL], or urinary\nl or k chains >12 g/day. Median survival \u000515 months\n\u0002\nSUBSTAGES\nA (Cr <175 mmol/L [ <1.9 mg/dL])\nand B (renal failure with Cr >175 mmol/L\n[>1.9 mg/dL])\nPROGNOSTIC FACTORS FOR MULTIPLE MYE\nLOMA\nb2 microglobulin, albumin, platelet, creati\nnine, and age. The international staging system for\nmultiple myeloma is particularly useful\n\u0002\nSTAGE I\nb2 microglobulin < 3.5 mg/L, albumin\n\u000635 g/L [\u00063.5 g/dL]. Median survival 62 months\n\u0002\nSTAGE II\nneither stage I nor III. Median survival 44\nmonths\n\u0002\nSTAGE III\nb2 microglobulin \u00065.5 mg/L. Median\nsurvival 29 months\nJCO 2005 23:15\nDIAGNOSTIC AND PROGNOSTIC ISSUES (CONT\u2019D)\nMultiple Myeloma\n179", "text_length": 4072, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 190/464)", "type": "chunk", "chunk_index": 189, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.506822", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.507753", "status": "complete", "chunks_added": 3}